| Dr Sarah Elizabeth Turner, MD | |
|
17296 Slover Ave, Fontana, CA 92337-7585 | |
| (909) 609-3000 | |
| Not Available |
| Full Name | Dr Sarah Elizabeth Turner |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 17296 Slover Ave, Fontana, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083891253 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QB0002X | Family Medicine - Obesity Medicine | A104979 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital Fontana/ontario | Fontana, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.
The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody "cocktail" to fight the deadly Ebola virus.
Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.
› Verified 7 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.
The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody "cocktail" to fight the deadly Ebola virus.
Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sarah Elizabeth Turner, MD 17296 Slover Ave, Fontana, CA 92337-7585 Ph: (909) 609-3000 | Dr Sarah Elizabeth Turner, MD 17296 Slover Ave, Fontana, CA 92337-7585 Ph: (909) 609-3000 |
News Archive
Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.
The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody "cocktail" to fight the deadly Ebola virus.
Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.
› Verified 7 days ago
Robert M. Theal, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Todd A. Westra, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Pushkar Chand, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Huy Phan, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Dr. Yolandie Mccoskey, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 909-427-2049 | |
William J. Delo, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
John R. Sharpe Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 |